Short‐Term Efficacy of Biologics in Recalcitrant Allergic Fungal Rhinosinusitis: A Systematic Review and Meta‐analysis
- 24 June 2025
- journal article
- review article
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 173 (4) , 840-847
Abstract
Objective: Allergic fungal rhinosinusitis (AFRS) is characterized by type I immunoglobulin E (IgE)‐mediated hypersensitivity reactions to fungal antigens. This systematic review and meta‐analysis assessed the efficacy of biologics in the management of refractory AFRS.Data Sources: PubMed, SCOPUS, Embase, Web of Science, and Cochrane.Review Methods: Changes in Sino‐Nasal Outcome Test (SNOT)‐22 scores, endoscopic findings, serum eosinophil count, and total IgE levels were assessed in patients with refractory AFRS after receiving biologic therapy. Subgroup analyses were conducted to evaluate the individual efficacy of each biologic agent, including dupilumab, mepolizumab, and omalizumab.Results: A total of 60 patients from 6 studies were analyzed. Biologics showed a significant improvement in SNOT‐22 scores (standard mean difference 1.1607 [95% CI 0.5549; 1.7664]), endoscopic scores (2.1953 [1.4181; 2.9725]), serum eosinophil count (1.1649 [0.7735; 1.5563]), and total IgE level (1.0700 [0.4052; 1.7348]). Dupilumab, mepolizumab, and omalizumab all enhanced SNOT‐22 and endoscopic scores. Additionally, dupilumab significantly reduced total IgE levels (1.2981 [0.4063; 2.1900]), whereas both dupilumab (0.9274 [0.1592; 1.6957]) and mepolizumab (1.2324 [0.9215; 1.5433]) significantly lowered the serum eosinophil counts.Conclusion: The agents significantly improved nasal symptoms, laboratory findings, and endoscopic scores. These findings support the potential role of biologics as a therapeutic option for patients with AFRS who are unresponsive to conventional treatments.Keywords
This publication has 38 references indexed in Scilit:
- Current Review of Comorbidities in Chronic RhinosinusitisCurrent Allergy and Asthma Reports, 2024
- Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents’ efficacyInternational Forum of Allergy & Rhinology, 2023
- Prolonged Itraconazole Therapy as Sole Treatment for Patients with Allergic Fungal RhinosinusitisThe Laryngoscope, 2023
- Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)Clinical and Translational Allergy, 2022
- What is allergic fungal sinusitis: A call to actionInternational Forum of Allergy & Rhinology, 2021
- Revisiting the controversy: The role of fungi in chronic rhinosinusitisInternational Forum of Allergy & Rhinology, 2021
- Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitisEuropean Archives of Oto-Rhino-Laryngology, 2019
- Omalizumab dampens type 2 inflammation in a group of long‐term treated asthma patients and detaches IgE from FcεRIEuropean Journal of Immunology, 2018
- Medical management of allergic fungal rhinosinusitis following endoscopic sinus surgery: an evidence‐based review and recommendationsInternational Forum of Allergy & Rhinology, 2014
- Modification of the lund‐kennedy endoscopic scoring system improves its reliability and correlation with patient‐reported outcome measuresThe Laryngoscope, 2014